Ruti Aga's Six-Year Ban Hinges on a Prescription That Never Existed

A half marathon in China, a March morning, and an Ethiopian woman crossing the line first. No race name in the record, no time, no splits, no field strength. What survives is this: she won, and the sample taken afterwards contained methylprednisolone. Some months later came the Athletics Integrity Unit statement — six years. Hold there a moment. Two of those six years are for what was in the sample. The other four are for a piece of paper submitted in her defence: a prescription carried in by a family member presented as a doctor, from a clinic that does not exist, written on an old pad that the clinic whose name it bore has explicitly disowned. In 23 years of reading results wires, doping cases split into two families — the ones where the substance is the argument, and the ones where the paperwork is. This belongs to the second family. Which is why it is being read wrong. Ruti Aga is 32. Her record is the 2026 Tokyo Marathon title and three second-place finishes at World Marathon Majors. That is a 2:18–2:20 marathoner — the layer immediately beneath the world's top tier, close enough to win a Major on the right day, never quite close enough to be an automatic Ethiopian selection. That is the first context worth having, because it decides what a six-year ban changes in the sport. The answer is almost nothing. Ethiopia's women's marathon depth is such that a 2:18 athlete sits behind a queue of world-record-class runners and is not picked by default. Her post-2026 racing pattern was selective Majors plus Asian label races — low race count, high appearance fee. The March half marathon in China is not a coincidence; it is that model working as designed. The second context is technical, and this is where the reporting has drifted. The substance is not an anabolic steroid. Methylprednisolone is a glucocorticoid, class S9 on the WADA Prohibited List, and S9 is prohibited in-competition only, by injection, oral or rectal route. A therapeutic knee injection out of competition is entirely lawful. Which means the case turned on route and timing, not on "steroid use." A road race's in-competition window opens at 23:59 the night before. An injection given days earlier becomes a violation only if residues are still present on race day. That was the defence available. The forged prescription closed it. Look at the arithmetic, because it explains the most. Two years for presence, four for tampering. That is the Code's standard architecture: two years where the substance is Specified and intent is not established, four as the standard tampering sanction. The panel found presence proven, declined the no-significant-fault mitigation, and treated the tampering as fully culpable. There is an oddity here that is going unremarked. A forged prescription is itself circumstantial evidence of concealment intent. It did not aggravate the presence sanction. The two penalties sit side by side rather than compounding — a detail that matters to anyone flattening this into doping plus lie equals six years. The ban runs from 10 September, the same date as the provisional suspension. Backdating is procedural relief, not a discount: the months already served are simply the months counted. From provisional suspension to reasoned decision is lived career time, not mercy. A CAS appeal window exists, typically around 21 days from the reasoned decision, but a document-based finding is the hardest kind to overturn, because the argument is about fact, not interpretation. Now the paper chain, because that is the real story. Three independent verification failures, in sequence. The prescribing "doctor" was a family member with no medical registration. The clinic named on the prescription did not exist. The claimed source of the pad — an old prescription pad from a former workplace — was denied by that workplace. Remove any one of the three and the four-year tampering charge does not stand. I went back to the tape to find the moment everyone missed, and here the tape is the interview, not the race. The AIU's tampering finding rests partly on statements made under questioning, not on the document alone. What she said became the heaviest thing she carried. Language and translation conditions in AIU interviews with East African road runners have been a recurring point of contention; this case reopens that argument even though the statement does not mention it. And from there the systemic question opens. The knee-injury explanation is mechanistically credible. Intra-articular methylprednisolone for knee synovitis is ordinary sports medicine in distance runners. That credibility is exactly why the forgery is decisive: a genuinely documented treatment gets defended with real records. A forged one signals an athlete with no credentialed team physician, no TUE preparation, no route-specific washout arithmetic. The knee trouble does not read like an acute March event. Manufacturing a paper trail suggests an informal treatment habit that was caught the day a sample was taken. Follow the money, then follow the people it forgot. Chinese label races are the income tier between Majors for East African marathoners — good appearance fees, low risk. That same tier is now the AIU's highest-yield testing ground. The fee economy and the testing economy are colliding in the same races, which means results from this tier now carry integrity risk. The March result and its prize money are very likely annulled under standard AIU practice, though the statement does not spell out the scope. The comfortable reading is that a cheat was caught, then lied, and is now paying. Six years sounds like justice. I read it the other way. The length deserves argument, but the real inconsistency is elsewhere. The substance at the centre of this case has no proven endurance benefit. A glucocorticoid reduces pain and swelling; it does not build muscle or carry oxygen. This is not a case about unfair advantage. It is a case about unfair documentation. Six years landed on the thing that does not make anyone faster — and that point will be quoted from both directions: as evidence of AIU rigour, and as evidence of disproportionate enforcement against African road runners. The second inversion is that the enforcement frontier has moved. The question used to be what was in the sample. The question now is whether the paper holds. That shift is more dangerous for athletes, because a sample can be argued scientifically while a document simply has to be right. Anyone without the right paper is standing at the four-year door. Anyone with it never appears in this story at all. I apply a falsification test to my own instinct. If the clinic had existed, the doctor had been registered, and the pad story had been true, this article would be about a timing error between treatment and race, and the sanction would likely be a reprimand or something very short. The evidentiary standard is clear, and it runs toward this reading rather than against it. What comes next. The arithmetic for Aga is brutal: six years from 10 September puts her return at roughly 38. In Ethiopia's women's marathon depth, a 38-year-old returning with a doping record is effectively unselectable. The 2028 Olympic cycle is closed. What remains is the 2026 Tokyo title and three Major runner-up finishes — the record of a genuinely elite marathoner, with a date now attached to it. The real question is not the athlete who was caught but the field she ran in. How many other 2:18 women are working through informal medical networks with no team doctor, no TUE literacy, and no idea how much distance belongs between an injection and a start line? Until that is answered, the AIU has one tool: catch the next one the same way, issue the same six years, and call the system working. The second post is where the real story usually hides. The first post here was a positive sample. The second post is a clinic that never existed.